Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4)

Overview of attention for article published in Thrombosis Research, March 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

blogs: 1 blog
patent: 5 patents

f1000: 1 research highlight platform

Readers on

mendeley: 75 Mendeley

So far, Altmetric has seen 3 posts from 1 blogs.

Factor IX product launched in US

HematologyTimes, 09 Feb 2018

Rebinyn® vialsPhoto from Novo…

Recombinant coagulation factor IX approved for hemophilia B

HematologyTimes, 07 Jun 2017

Antihemophilic factorNonacog beta pegol (N9-GP, Rebinyn®), a recombinant, GlycoPEGylated cogulation factor IX, has been…

CHMP recommends product for hemophilia B

HematologyTimes, 26 Mar 2017

Antihemophilic factorThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.